The young company Xeltis, headquartered in Zurich, focuses on the globally standardized implantation of heart valves. Bioabsorbable valves and vessels have been developed from the medical technology research facility, which enable the body’s own tissue to renew itself and finally degrade the implant. This can reduce the number of procedures following heart surgery and improve patients’ quality of life. The applications are still in the clinical trial phase. The results of the first 5-year-old patient are encouraging and have enabled the transition to further study phases.
Within a decade, the company has evolved from a spin-off of the University of Zurich into one of the world’s most promising medical technology companies, having been included in the renowned Fierce 15 list. Life Science Communication supports Xeltis with strategy consulting and media relations.
